Searched for
DIABETIC DYSLIPIDEMIA
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in IndiaZydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...
- Cholesterol test at age 18, Non-fasting measurement: Cardiologists Suggest New Guidelines on how to prevent heart attacksThe Cardiologist Society of India (CSI) now recommends lipid profiles starting at age 18, with non-fasting measurements as the new norm. Th...
- Apollo Hospitals launches AI-driven personalised preventive health profileApollo's 'ProHealth' program is backed by a predictive algorithm that captures one’s health status, predicts potential health risks and ind...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- Zydus Cadila gets DCGI nod for world's first drug to treat liver diseaseThe Ahmedabad-based company said the approved product is the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoh...
- Zydus Cadila files NDA for Saroglitazar MagnesiumNASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...
- Zydus launches Tenglyn tablets in Indian marketDrug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in ...
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...
- Zydus Cadila Q2 net profit up by 94%Besides Lipaglyn, the group launched 19 new products, including line extensions in India of which, four were first in India.
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.
- Zydus to launch first new chemical entity by desi companyCadila Healthcare on Wednesday said that its new chemical entity (NCE), Lipaglyn , has been approved by the Drug Controller General of Indi...
- Zydus Cadila gets DCGI nod for launch of its NCE for diabetesCadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes
- Zydus Cadila to launch molecule for diabetesPharma major Cadila Healthcare may soon become one of a handful of Indian companies to launch an indigenously developed molecule.
- Cadila files new drug application; share up nearly 1%Cadila Healthcare has filed an investigational new drug application for conducting clinical trials for molecular entity - ZYH7, to treat dy...
Load More
